# QTRX earnings call intelligence

LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/QTRX) · [Earnings tab](https://www.lopjlb.com/stock/QTRX?tab=earnings)

Updated: 2026-08-10T11:24:35

Quarters analyzed: 8

## Cross-quarter narrative

Across eight quarterly CallCards Quanterix’s story shifts from early‑year revenue momentum to a mid‑year contraction and a later rebound. Q1‑2024 showed 13% top‑line growth driven by consumables and the Accelerator Lab, with FY24 guidance held steady. By Q1‑2025 revenue slipped 5% as academic funding cuts and NIH budget reductions pressured the core market, prompting a lowered FY24 outlook. The downturn deepened in Q2‑2025 with a 29% YoY drop, reflecting weaker pharma projects, reduced instrument placements and tariff headwinds. A turnaround began in Q3‑2025, posting 12% growth as Akoya integration accelerated and synergies materialized. Margins rose from 53.4% (Q3‑2024) to 57.7% (Q4‑2024) on consumable mix shifts, then faced compression as demand fell, but cost‑saving actions kept them stable. The Akoya acquisition moved from on‑track to delivered, unlocking $85‑$90 M of synergies. Product progress remained steady: LucentAD Complete and p‑Tau217 submissions stayed on track, Simoa ONE launch stayed on schedule, and new Alzheimer’s assays entered early‑access. Throughout, the company kept its cash‑flow‑breakeven‑by‑2026 goal, with capital allocated to diagnostics and integration while navigating persistent academic funding and regulatory risks.

## Latest CallCard · Q1

**Guidance:** vague

**Tone:** mgmt 0 · Q&A pressure 0 · divergence 0

## Quarter one-liners

- **2026 Q1:** —
- **2025 Q4:** New CEO Cunningham emphasizes diversification, cost synergies ($85M by Q1), and Alzheimer's diagnostics (LucentAD CMS $897, 510(k) filed) while guiding 2026 revenue $169-174M (~2% growth ex-terminated deal) and H2 cash breakeven.','tone': {'mgmt': 0.3, 'mgmt_rationale': 'Cunningham expresses confide
- **2025 Q3:** Quanterix Q3 revenue $40.2M (+12% YoY) with Akoya integration ahead of plan ($67M/$85M synergies), but core Simoa consumables down 36% organically on smaller academic/pharma orders; FY25 guidance maintained $130-135M, targeting $120M cash year-end, cash flow breakeven 2026.','tone': {'mgmt': 0.3, 'm
- **2025 Q2:** Quanterix reported Q2 revenue of $24.5M, down 29% YoY, highlighted Akoya acquisition synergies, cost‑saving actions and guidance for $130‑135M revenue in 2025 with a cash‑flow breakeven target in 2026.
- **2025 Q1:** Q1 revenue fell 5% to $30.3M but consumables grew, management lowered full-year guidance amid academic funding cuts, announced Akoya merger, Simoa ONE launch and aims for positive cash flow by 2026.
- **2024 Q4:** Quanterix posted 11% Q4 revenue growth, expanded non‑GAAP margin to 57.7%, announced a Q2 2025 Akoya acquisition and a 2025 launch of Simoa ONE, while flagging US academic headwinds and a slower first‑half Accelerator pipeline.
- **2024 Q3:** QTRX Q3 revenue $35.7M (+13% YoY), reaffirmed FY24 guidance $134-138M; non-GAAP gross margin 53.4% (+160bps); advancing Alzheimer's multi-marker LDT LucentAD Complete, FDA p-Tau217 submission progressing; restatement underway. Cash $296M, burn $3.3M.
- **2024 Q1:** Quanterix Q1 revenue $32M (+13%) driven by consumables (+22%) and Accelerator Lab (+57%), offsetting instrument weakness; reiterated FY24 guidance $139-144M; advancing ~20 new biomarker assays, BD-tau launch this quarter, multi-marker test progress.','tone': {'mgmt': 0.3, 'mgmt_rationale': 'Manageme

## Theme arcs

- **Revenue trajectory** (deteriorating): Growth in 2024 turned to double‑digit declines in early 2025, then modest recovery in Q3‑2025
- **Akoya acquisition integration** (improving): From on‑track in Q4‑2024 to delivered and synergies realized by Q2‑2025
- **Funding environment pressure** (deteriorating): Academic and NIH funding cuts repeatedly cited as revenue headwinds
- **Cash‑flow breakeven target** (improving): Consistent focus on cost cuts and synergies to achieve breakeven in 2026
- **Product pipeline advancement** (improving): LucentAD Complete, p‑Tau217, and Simoa ONE remained on schedule
- **Instrument demand weakness** (deteriorating): Instrument placements fell sharply and remained weak through 2025

## Fear persistence

- **Academic funding/headwinds** [recurring]: Cited in Q4‑2024, Q1‑2025 and Q2‑2025
- **Acquisition valuation risk** [resolved]: Mentioned only in Q4‑2024
- **Integration risk** [recurring]: Appears Q4‑2024 through Q2‑2025
- **Regulatory risk (LucentAD FDA)** [resolved]: Only in Q4‑2024

## Guidance path

2024 Q1:vague → 2024 Q3:maintained → 2024 Q4:maintained → 2025 Q1:lowered → 2025 Q2:maintained → 2025 Q3:vague → 2025 Q4:vague → 2026 Q1:vague

---

Research context only. Not personalized investment advice.

API: `GET /bff/api/bigfive/earnings-intel/QTRX`